Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for ...
B/F/TAF shows lower ART switching rates and higher persistence among HIV patients, especially those with mental health or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback